Eikon Therapeutics Q3 2026 Results: Net Loss of $86.1M, Loss Widens
Eikon Therapeutics is a late clinical-stage biotechnology company that has not yet generated revenue from product sales and continues to incur substantial net losses. The filing highlights the development of its lead product candidates, including EIK1001 and EIK1003, and notes a restatement of financial statements for the nine months ended September 30, 2025, due to a material weakness in internal controls.
- Key figure
- Net loss $86.1M